Invitris is revolutionizing biotechnology with its cell-free protein synthesis platform, enabling rapid design, expression, and scalable production of complex proteins beyond the limitations of traditional cell-based systems. This innovative approach accelerates drug discovery and development, particularly in combating antimicrobial resistance. Key Features and Functionality: - Prokaryotic Cell-Free Expression System: Utilizes Phactory™ reagents for high-yield protein expression, optimized for microbial proteins such as enzymes, phages, endolysins, tailocins, and binders. - Mammalian Cell-Free Expression System: Facilitates the production of complex proteins with post-translational modifications like glycosylation and disulfide bonds, eliminating the need for complex transfection protocols and enabling scalable, high-yield expression of difficult-to-express proteins. - Ultra High-Throughput Screening: Employs microfluidics technology to screen up to 1,000 proteins per second, significantly enhancing the efficiency of protein engineering. - Rapid Protein Engineering: Integrates computational design with high-throughput screening to expedite the sequence-to-structure process. - Translational Protein Production: Offers seamless scalability from picoliter reactions to liter-scale production, ensuring flexibility across various stages of development. Primary Value and Solutions Provided: Invitris addresses critical challenges in biotechnology by providing a versatile platform that accelerates the development and production of protein-based therapeutics. By overcoming the constraints of cell-based expression systems, Invitris enables the creation of novel treatments for antimicrobial resistance and other pressing health concerns. Their technology supports diverse applications across sectors such as biopharmaceuticals, industrial biotechnology, and agriculture, fostering innovation and efficiency in research and development.